Acuta Capital Partners’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Acuta Capital Partners’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-19,500	Closed	-$157K	–	58
2023 Q3	$157K	Buy	+19,500	New	+$162K	0.11%	43
2020 Q2	–	Sell	-259,500	Closed	-$2.11M	–	49
2020 Q1	$2.11M	Buy	+259,500	New	+$2.25M	1.02%	26
2015 Q2	–	Sell	-9,027	Closed	-$325K	–	61
2015 Q1	$325K	Buy	+9,027	New	+$396K	0.27%	48

Other funds holding MRNS

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Acuta Capital Partners's MRNS Position: Q4 2023 in Review

Acuta Capital Partners sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2023, closing a stake of 19,500 shares — an estimated $157K sold.

Acuta Capital Partners first reported a position in MRNS in Q1 2015 and held it in 3 quarters. The position peaked at $2.11M in Q1 2020. 105 funds tracked by Wall St. Rank hold MRNS as of Q4 2023.

Acuta Capital Partners reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
Acuta Capital Partners sold 19,500 Marinus Pharmaceuticals, Inc shares in Q4 2023, an estimated $157K.
Acuta Capital Partners first reported a position in Marinus Pharmaceuticals, Inc in Q1 2015 and held it in 3 quarters.
Acuta Capital Partners's Marinus Pharmaceuticals, Inc position peaked at $2.11M in Q1 2020.
105 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2023.

Based on Acuta Capital Partners's 13F filing for Q4 2023, filed 14 Feb 2024.